Validation and Application of an HPLC-UV Method for Routine Therapeutic Drug Monitoring of Cefiderocol.
Julia ZimmerAnka C RöhrStefan KlugeJonas FallerOtto R FreyDominic WichmannChristina KoenigPublished in: Antibiotics (Basel, Switzerland) (2021)
Cefiderocol is a new siderophore cephalosporin approved for the treatment of multidrug resistant bacteria including activity against carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa. As cephalosporins are known for their high pharmacokinetic variability in critically ill patients, cefiderocol therapeutic drug monitoring might become a valuable tool. Therefore, we aimed to develop and validate a simple, rapid, cost-effective high performance liquid chromatography (HPLC) method for the quantification of cefiderocol in serum. Samples were treated for protein precipitation followed by chromatographic separation on a reverse phase column (HPLC C-18) with gradient elution of the mobile phase. Cefiderocol was detected via UV absorption and quantification was performed with the internal standard (metronidazole) method. The calibration range showed linearity from 4 to 160 mg/L. The intra and interday precision was less than 10% with a recovery rate of 81%. The method was successfully used for the analysis of subsequent serum samples of critically ill patients and showed good performance in monitoring serum levels and optimizing antibiotic therapy.
Keyphrases
- quantum dots
- gram negative
- high performance liquid chromatography
- multidrug resistant
- simultaneous determination
- solid phase extraction
- tandem mass spectrometry
- ms ms
- mass spectrometry
- liquid chromatography
- acinetobacter baumannii
- pseudomonas aeruginosa
- drug resistant
- escherichia coli
- cystic fibrosis
- clinical practice
- high resolution
- bone marrow
- stem cells
- replacement therapy